A carrier screening report is a document written in the language of laboratory genetics. It contains terms like 'pathogenic variant', 'variant of uncertain significance', 'heterozygous carrier' and numbers that mean nothing without context. Most people who receive such a document feel either anxiety or confusion. Sometimes both at once.
The good news: the structure of these reports is broadly consistent across laboratories, and most results — even those that look alarming — mean exactly what they should in a normal context. Let's go through it section by section.
A standard expanded carrier screening report contains several sections. First, the list of genes and conditions tested — everything that was checked. This may be 100, 300 or 500+ entries. Don't be put off by the length: a longer list is a good thing. It means more has been checked.
Second, the summary — the most important part of the document. This is where the laboratory reports whether carrier status has been detected for any variants, and if so, which ones. Third, detail on each identified variant (if any). Fourth, recommendations — usually a standard statement about consulting a geneticist.
No carrier status detected / Negative — you are not a carrier of any of the tested variants. This is the most common result. Important to remember: this does not mean 'absolutely zero risk' — the test does not cover 100% of all possible mutations, and there are conditions not included in the panel. But for all tested conditions, the risk is minimal.
Carrier detected — you carry one pathogenic variant in one of the tested genes. This is not a disease. You are healthy. It means you have one 'working' and one 'altered' copy of the gene. The significance of this result depends entirely on your co-parent or partner's status for the same gene.
Affected — two pathogenic variants have been found in one gene. This means you may yourself be susceptible to the condition, not merely a carrier. This is a rare outcome from screening (such situations are usually diagnosed differently), but it is possible — for example, with mild forms of certain conditions.
Variant of Uncertain Significance (VUS) — arguably the hardest result to understand. It means: the laboratory found a change in the gene, but science does not yet have sufficient data to confidently classify it as pathogenic or benign. A VUS is not a diagnosis and not a sentence. It means 'we don't know yet.' As data accumulates, many VUS results are reclassified — more often as benign than pathogenic.
Good laboratory reports include, after each negative result for a condition, what is known as residual risk — the probability that you are still a carrier despite the negative test. Why is this not zero? Because no panel covers all possible pathogenic variants in a gene — only the most well-known and frequent ones.
For example, for cystic fibrosis, a standard panel covers approximately 95% of pathogenic variants in the CFTR gene in people of European descent. The residual carrier risk after a negative test is approximately 1 in 500 instead of the baseline 1 in 25. That is an enormous reduction in risk. But it is not zero. This number is worth knowing — it shows the real level of confidence, not the illusion of an absolute guarantee.
If you turn out to be a carrier of some variant — the next step depends on whether your prospective co-parent or partner has been screened. If not — this is the reason for their testing. The specific condition for which you are a carrier should be checked first.
If the partner has been tested and is not a carrier of the same variant — the risk to a child is zero for that condition. The child may become a carrier (with 50% probability) but will not be ill. If the partner has not been tested — the unknown does not equal risk. It equals a reason for a test.
If both partners turn out to be carriers of the same recessive variant — this is called joint carrier status and means a 25% risk for each pregnancy. This is not a catastrophe and not a prohibition on parenthood. It is information to work with.
The next step is a consultation with a clinical geneticist. The specialist will explain the specific risk figures for your condition, outline available options (IVF with PGT, donation, prenatal diagnosis) and help you make a decision suited to your circumstances. Important: the consultation should happen before any decisions are made, not after.
In the detailed section of the report, for each identified variant the laboratory states its classification. The international system (developed by the American College of Medical Genetics, ACMG) has five classes: Pathogenic — variant with proven association with disease; Likely pathogenic — high probability of association, but not absolute proof; Variant of Uncertain Significance (VUS) — as described above; Likely benign — probably neutral; Benign — neutral, no clinical significance.
In the context of carrier screening, only the first two classes — pathogenic and likely pathogenic — are clinically relevant. A VUS generally does not affect recommendations, though it warrants monitoring. Benign variants are simply normal genomic variation.
Negative across all positions: nothing specific to do. Save the report. If the partner has not been tested — it is their turn. Carrier of one variant, partner not tested: priority is testing the partner for that specific condition. Carrier of one variant, partner is not a carrier: no risk to a child, no further steps required. VUS detected: discuss with a geneticist, do not panic. Joint carrier status in both partners: consultation with a geneticist before any decisions.
A carrier screening report is not a medical verdict. It is an analytical document describing probabilities. Most people receive a negative result. Those who discover carrier status most commonly face a 'one carrier of two' situation — with no risk to a child. Joint carrier status in both partners is not a dead end. It is a point for making an informed decision. Read the results calmly. And ideally — together with the person who will be alongside you in this parenting project.